187 related articles for article (PubMed ID: 38328189)
1. A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN.
Ellison V; Polotskaia A; Xiao G; Leybengrub P; Qiu W; Lee R; Hendrickson R; Hu W; Bargonetti J
bioRxiv; 2024 Jan; ():. PubMed ID: 38328189
[TBL] [Abstract][Full Text] [Related]
2. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
3. Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis.
Gao C; Xiao G; Bargonetti J
Oncotarget; 2019 Aug; 10(49):5007-5010. PubMed ID: 31489110
[TBL] [Abstract][Full Text] [Related]
4. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
[TBL] [Abstract][Full Text] [Related]
5. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
[TBL] [Abstract][Full Text] [Related]
6. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
[TBL] [Abstract][Full Text] [Related]
8. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
[TBL] [Abstract][Full Text] [Related]
9. MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
Loo LWM; Gao C; Shvetsov YB; Okoro DR; Hernandez BY; Bargonetti J
Breast Cancer Res Treat; 2019 Feb; 174(1):257-269. PubMed ID: 30470976
[TBL] [Abstract][Full Text] [Related]
10. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
11. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after γ-irradiation that depleted MDC1 protein in specific TP53 mutants.
Suchánková J; Legartová S; Ručková E; Vojtěšek B; Kozubek S; Bártová E
Histochem Cell Biol; 2017 Sep; 148(3):239-255. PubMed ID: 28397142
[TBL] [Abstract][Full Text] [Related]
13. Mdmx promotes genomic instability independent of p53 and Mdm2.
Carrillo AM; Bouska A; Arrate MP; Eischen CM
Oncogene; 2015 Feb; 34(7):846-56. PubMed ID: 24608433
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
15. MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.
Henningsen KM; Manzini V; Magerhans A; Gerber S; Dobbelstein M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053170
[TBL] [Abstract][Full Text] [Related]
16. Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.
Berke TP; Slight SH; Hyder SM
Onco Targets Ther; 2022; 15():23-30. PubMed ID: 35035222
[TBL] [Abstract][Full Text] [Related]
17. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
19. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
[TBL] [Abstract][Full Text] [Related]
20. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]